Início › Melanoma › Minnesota › Rochester
Ensaios clínicos de Melanoma em Rochester, MN
16 estudos para Melanoma estão buscando participantes em locais em Rochester e arredores (num raio de aproximadamente 30 milhas). Abra um estudo para ver quem pode participar e como contatar a equipe.
Texto oficial do estudo (Inglês)
Recrutando participantes para um estudo? Destaque-o no topo desta página — $99 por 30 dias →
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
RecrutandoFase 2
- Mayo Clinic in Rochester, Rochester
Pan-tumor MRD Study
RecrutandoEstudo observacional
- Mayo Clinic, Rochester
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
RecrutandoFase 2
- Local Institution - 0129, Rochester
- Local Institution - 0174, Rochester
- Local Institution - 0181, Rochester
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
RecrutandoEstudo observacional
- Mayo Clinic (Rochester), Rochester
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
RecrutandoFase 1
- Mayo Clinic - Rochester, Rochester
Project: Every Child for Younger Patients With Cancer
RecrutandoEstudo observacional
- Mayo Clinic in Rochester, Rochester
Digital Remote Monitoring of Immune Checkpoint Inhibitor Therapy Induced Toxicity Using the Vigilant App
RecrutandoEstudo observacional
- Mayo Clinic in Rochester, Rochester
Studying Quality of Life Inclusive of Mental Health and Cognitive Behavioral Therapy for Cancer Distress for the Improvement of Quality of Life in Stage III-IV Melanoma Patients
Recrutando
- Mayo Clinic in Rochester, Rochester
Evaluation of Anti-PD-1 Therapy by Monitoring T Cell Responses in Melanoma, Lung and Other Cancer Types
RecrutandoEstudo observacional
- Mayo Clinic in Rochester, Rochester
MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma
RecrutandoFase 1/2
- Mayo Clinic Rochester, Rochester
Neoadjuvant Darovasertib in Primary Uveal Melanoma
RecrutandoFase 3
- Mayo Clinic - PPDS, Rochester
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
RecrutandoFase 2/3
- Mayo Clinic Rochester, Rochester
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
RecrutandoEstudo observacional
- Mayo Clinic, Rochester
Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
RecrutandoFase 3
- Mayo Clinic Minnesota, Rochester
Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients
RecrutandoFase 3
- Mayo Clinic, Rochester
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
RecrutandoFase 1/2
- Mayo Clinic in Minnesota, Rochester
Ensaios de Melanoma em outras cidades
- Houston, TX59 estudos
- New York City, NY38 estudos
- Los Angeles, CA34 estudos
- Nashville, TN33 estudos
- Pittsburgh, PA31 estudos
- Boston, MA26 estudos
- Philadelphia, PA23 estudos
- San Francisco, CA22 estudos
- Atlanta, GA21 estudos
- Durham, NC21 estudos
- St. Louis, MO21 estudos
- Columbus, OH21 estudos
Outros estudos em Rochester
- Câncer de Mama42 estudos
- Câncer de Pulmão de Não Pequenas Células37 estudos
- Câncer Metastático31 estudos
- Câncer (todos os tipos)30 estudos
- Câncer Colorretal29 estudos
- Câncer de Ovário29 estudos
- Mieloma Múltiplo24 estudos
- Câncer de Próstata22 estudos
- Insuficiência Cardíaca22 estudos
- Câncer de Pâncreas22 estudos
- Câncer de Pulmão20 estudos
- Câncer Endometrial20 estudos
Fonte: ClinicalTrials.gov, dados obtidos em 5 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.